Homepage Top Section2

The partnership targets membrane proteins, intracellular protein–protein interactions and complex receptor systems through a new drug discovery platform. It aims to target disease areas where conventional small-molecule drug

Neupharma will gain exclusive rights for the development and commercialisation of the therapy, addressing a condition currently lacking approved targeted treatments. The company will fund and conduct a

As part of the agreement, Idorsia will receive an upfront payment and retain marketing authorisations in each country. Following local regulatory approval, the company will supply the finished

Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight. It is

This approval applies to patients who have undergone at least one prior treatment, including a proteasome inhibitor and an immunomodulatory agent. It aims to provide a new standard

Alprazolam is the active pharmaceutical ingredient (API) in Xanax, a commonly prescribed anti-anxiety medication. Traditional oral alprazolam tablets can require 25 minutes or more to take effect, as

CL-273 is a reversible, investigational, wild-type-sparing pan epidermal growth factor receptor (EGFR) small molecule inhibitor developed using an AI-based drug discovery platform. The asset specifically targets resistant mutations

The acquisition will expand the company’s speciality pharmaceutical platform into severe infectious diseases. Completion is expected in the first quarter of fiscal 2026, subject to customary conditions. The

The acquisition includes five sites specialising in various in vitro drug discovery services such as New Approach Methodologies (NAMs) and a small molecule AI platform. These assets are